Connect with us

Technology

Illumina addresses recent developments in China

Published

on

Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Approximately $4.50

SAN DIEGO, March 10, 2025 /PRNewswire/ — Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today responded to the March 4, 2025 notice from the China Ministry of Commerce (“MOFCOM”) that Illumina is not permitted to export sequencing instruments into China. Illumina respects MOFCOM’s decision and will continue to comply with all applicable laws and regulations wherever the company operates. Illumina has had a long-standing presence in China, and the company continues to serve its clinical and research customers there.

“We remain focused on achieving high-single-digit revenue growth by 2027, while expanding our margins,” said Jacob Thaysen, CEO of Illumina. “We are confident in the large global market opportunity for our solutions, the strength of our business, and our strategy to continue to lead innovation in genomics and multiomics in support of our customers.”

As the company recently highlighted, Illumina will continue expanding its multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, and methylation, as well as a new multimodal data analysis platform. These solutions leverage the power of Illumina’s leading NovaSeq X series platform and will enable researchers to derive breakthrough insights around the drivers of disease. The company will also continue to invest in its services, data, and software offerings that support its core sequencing and multiomics businesses. Each of these efforts supports Illumina’s customers’ important work and underpins Illumina’s strategy as presented during its August 2024 Strategy Update.

Illumina also announced it expects Core Illumina fiscal 2025 non-GAAP diluted EPS of approximately $4.50. The company is instituting an incremental approximately $100 million cost reduction program for fiscal 2025. These savings would mitigate the impact of a range of potential scenarios for a reduction in revenue and related operating income from the company’s Greater China business. The cost reduction program includes optimizing stock-based compensation and non-labor spending and accelerating certain productivity measures.

“Our new fiscal 2025 guidance provides for limited further earnings contribution from China, and assumes a continuation of the macro trends we see today,” said Ankur Dhingra, CFO of Illumina. “We will continue to invest in our growth strategy, while taking actions to achieve EPS of approximately $4.50 in 2025, and then grow from there.”

Financial outlook and guidance
The company provides forward-looking guidance on a non-GAAP basis. The company is unable to provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures because it is unable to predict with reasonable certainty the impact of items such as acquisition-related expenses, gains and losses from strategic investments, fair value adjustments to contingent consideration, potential future asset impairments, restructuring activities, and the ultimate outcome of pending litigation without unreasonable effort. These items are uncertain, inherently difficult to predict, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, the company is unable to address the significance of the unavailable information, which could be material to future results.

Statement regarding use of non-GAAP financial measures
The company reports non-GAAP results for diluted earnings per share, net income, gross margin, operating expenses, including research and development expense, selling general and administrative expense, legal contingencies and settlement, and goodwill and intangible impairment, operating income, operating margin, gross profit, other income (expense), tax provision, constant currency revenue growth, and free cash flow (on a consolidated and, as applicable, segment basis) in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company’s financial measures under GAAP include substantial charges such as amortization of acquired intangible assets, among others, as well as the effects of currency translation. Management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance. Non-GAAP net income, diluted earnings per share and operating margin are key components of the financial metrics utilized by the company’s board of directors to measure, in part, management’s performance and determine significant elements of management’s compensation.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information, to more fully understand its business.

Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) uncertainty regarding the impact of our recent inclusion by the China Ministry of Commerce (“MOFCOM”) announcement that Illumina is included on its “unreliable entities list,” MOFCOM’s decision not to permit us to export sequencing instruments into China, as well as tariffs recently imposed or threatened by the U.S. government and its trading partners, and other possible tariffs or trade protection measures; (v) our ability to manufacture robust instrumentation and consumables; (vi) the success of products and services competitive with our own; (vii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (viii) the impact of recently launched or pre-announced products and services on existing products and services; (ix) our ability to modify our business strategies to accomplish our desired operational goals; (x) our ability to realize the anticipated benefits from prior or future actions to streamline and improve our R&D processes, reduce our operating expenses and maximize our revenue growth; (xi) our ability to further develop and commercialize our instruments, consumables, and products; (xii) to deploy new products, services, and applications, and to expand the markets for our technology platforms; (xiii) the risk of additional litigation arising against us in connection with the GRAIL acquisition; (xiv) our ability to obtain approval by third-party payors to reimburse patients for our products; (xv) our ability to obtain regulatory clearance for our products from government agencies; (xvi) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xvii) uncertainty, or adverse economic and business conditions, including as a result of slowing or uncertain economic growth or armed conflict; (xviii) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments and (xix) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.    

Investors:
Salli Schwartz
+1.858.291.6421
ir@illumina.com

Media:
Bonny Fowler
+1.740.641.5579
pr@illumina.com

View original content:https://www.prnewswire.com/news-releases/illumina-addresses-recent-developments-in-china-302397466.html

SOURCE Illumina, Inc.

Continue Reading

Technology

Millennium Dental Technologies and Institute for Advanced Laser Dentistry Mourn Passing of Professor Raymond A. Yukna, DMD, MS (1942-2026)

Published

on

By

CERRITOS, Calif., Oct. 30, 2026 /PRNewswire/ — It is with profound sadness that Millennium Dental Technologies and the Institute for Advanced Laser Dentistry (IALD) mourn the passing of Professor Raymond A. Yukna, DMD, MS, world-renowned clinician, educator, researcher, mentor and cherished friend.

Throughout a remarkable career spanning academia, research, clinical practice and education, Dr. Yukna earned the admiration of colleagues worldwide for his unwavering commitment to scientific inquiry, clinical excellence and the advancement of patient care.

A Diplomate of both the American Board of Periodontology and the American Board of Oral Medicine, Professor of Advanced Periodontal Therapies at the University of Colorado School of Dental Medicine, Professor Emeritus at Louisiana State University, internationally recognized lecturer, and respected researcher, Dr. Yukna devoted his life to advancing the field of periodontics. His contributions helped shape modern periodontal therapy and influenced generations of clinicians, educators, and researchers worldwide.

His reputation for integrity, scientific rigor and thoughtful leadership made him one of the most trusted and respected voices in the specialty.

A DEFINING CHAPTER IN THE HISTORY OF THE LANAP® PROTOCOL

Dr. Yukna brought credibility, intellectual curiosity and scientific discipline that would help shape the future of the LANAP® protocol, a minimally invasive laser treatment for the treatment of moderate to severe periodontal disease. He engaged in thoughtful dialogue with Millennium Dental Technologies Co-Founders Robert H. Gregg II, DDS, and Delwin K. McCarthy, DDS, regarding the emerging science behind laser-assisted periodontal regeneration.

His groundbreaking research provided some of the earliest and most influential human histological evidence supporting the LANAP® protocol. Beginning with his International Association for Dental Research (IADR) abstract in 2003, followed by the submission of his landmark study to the International Journal of Periodontics and Restorative Dentistry (IJPRD) in 2006 and its publication in 2007, Dr. Yukna produced research that became a defining milestone in the scientific validation of the LANAP® protocol. His work demonstrated cementum-mediated new connective tissue attachment in humans and provided the periodontal community with compelling evidence supporting the protocol’s regenerative potential.

At a time when laser periodontal therapy was met with understandable skepticism by many within the specialty, Dr. Yukna’s willingness to objectively evaluate the science—and ultimately contribute his own landmark research—gave the LANAP® protocol a level of scientific credibility that helped change its trajectory. Many periodontists first embraced the LANAP® protocol because they trusted Dr. Yukna’s scientific integrity and respected his commitment to evidence-based dentistry.

His landmark study opened the door to broader acceptance of the LANAP® protocol within periodontics and laid the foundation for additional human histological studies, expanded university research efforts, and more than two decades of continued scientific investigation. The growing body of evidence supporting the LANAP® protocol today owes much to the foundation Dr. Yukna helped establish.

A TEACHER WHO SHAPED A GENERATION

Dr. Yukna’s influence extended far beyond the published literature. As an IALD Certified Instructor, he became one of the most influential educators in the history of the LANAP® protocol. He served as hands-on clinical instructor for approximately 350 LANAP-trained clinicians and lectured at roughly 130 Laser BootCamps™, helping educate well over 1,000 clinicians throughout his years with the IALD and Millennium Dental Technologies.

From the Denver BootCamps™ held during his tenure at the University of Colorado School of Dental Medicine to sessions conducted throughout New York and, later, at the facility in Cerritos, Dr. Yukna’s lectures, mentorship and quiet confidence inspired countless clinicians. His generosity in sharing his knowledge, his thoughtful guidance and his commitment to excellence helped shape the careers of an entire generation of LANAP clinicians.

A CHERISHED FRIEND

Beyond his extraordinary professional accomplishments was an even more extraordinary person. For Robert H. Gregg II, DDS and Dawn Gregg, DDS, Dr. Yukna and his wife, Charlotte, were not simply respected colleagues, they were dear friends. Over many years, they shared milestones, celebrated successes, supported one another through challenges and built a friendship that extended far beyond dentistry. In fact, when Dr. Robert Gregg and Dr. Dawn Gregg began their lives together as a couple, Dr. Yukna and Charlotte were among the very first people they chose to tell in person—reflecting the trust, respect and affection they shared.

Those privileged to know Dr. Yukna personally will remember far more than his curriculum vitae. They will remember his humility, kindness, generosity, wisdom, quiet confidence and unwavering integrity. He challenged those around him to pursue excellence, to follow the science wherever it led, and to never lose sight of the patients whose lives could be changed through innovation grounded in evidence.

HIS LEGACY LIVES ON

The LANAP® community, the periodontal profession, the IALD and the entire Millennium Dental Technologies family are better because of Dr. Yukna’s contributions.

His legacy lives on through the science he advanced, the clinicians he trained, the patients whose lives were improved by his work, and the countless colleagues and friends he inspired throughout his remarkable career.

Millennium Dental Technologies and the IALD extends deepest condolences to Charlotte and Dr. Yukna’s family, friends, colleagues, students and all those whose lives he touched.

Thank you, Dr. Yukna, for your leadership, your scholarship, your mentorship, your friendship, and your unwavering belief that scientific excellence could improve the lives of patients around the world.

ABOUT MILLENNIUM DENTAL TECHNOLOGIES, INC.

Headquartered in Cerritos, Calif., Millennium Dental Technologies is the developer of the LANAP protocol for treating periodontal disease and the manufacturer of the PerioLase MVP-7 variable-pulsed Nd:YAG dental laser. The company’s FDA-cleared LANAP protocol offers a more comfortable, less invasive alternative to conventional periodontal surgery while providing unique bone-building clinical results. Founding clinician Robert H. Gregg II, DDS, continues to lead the company with a vision to create better clinical outcomes for patients with periodontal disease while remaining true to its guiding principle: “It’s all about the patient.” For more information, visit www.lanap.com.

ABOUT THE INSTITUTE FOR ADVANCED LASER DENTISTRY

The Institute for Advanced Laser Dentistry is a nonprofit educational and research organization dedicated to advancing evidence-based clinical training in laser dentistry. Established in 1999, the IALD is nationally recognized for its continuing education programs as an ADA Continuing Education Recognition Program and Academy of General Dentistry Program Approval for Continuing Education provider. For more information, visit www.theiald.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/millennium-dental-technologies-and-institute-for-advanced-laser-dentistry-mourn-passing-of-professor-raymond-a-yukna-dmd-ms-1942-2026-302925319.html

SOURCE Millennium Dental Technologies, Inc.

Continue Reading

Technology

Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Published

on

By

NEW YORK, Oct. 30, 2026 /PRNewswire/ — S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on Wednesday, November 4:

S&P MidCap 400 constituent Okta Inc. (NASD: OKTA) will replace Kenvue Inc. (NYSE: KVUE) in the S&P 500, S&P SmallCap 600 constituent Glaukos Corp. (NYSE: GKOS) will replace Okta in the S&P MidCap 400, and McGrath RentCorp (NASD: MGRC) will replace Glaukos in the S&P SmallCap 600. S&P 500 constituent Kimberly-Clark (NASD: KMB) is acquiring Kenvue in a deal expected to be completed soon, pending final closing conditions.Loar Holdings Inc. (NYSE: LOAR) will replace LiveRamp Holdings Inc. (NYSE: RAMP) in the S&P SmallCap 600. Publicis Groupe SA (Euronext Paris: PUB) is acquiring LiveRamp Holdings in a deal expected to close soon, pending final closing conditions.

Following is a summary of the changes that will take place prior to the open of trading on the effective date:

Effective Date

Index Name 

Action

Company Name

Ticker

GICS Sector

Nov 4, 2026

S&P 500

Addition

Okta

OKTA

Information Technology

Nov 4, 2026

S&P 500

Deletion

Kenvue

KVUE

Consumer Staples

Nov 4, 2026

S&P MidCap 400

Addition

Glaukos

GKOS

Health Care

Nov 4, 2026

S&P MidCap 400

Deletion

Okta

OKTA

Information Technology

Nov 4, 2026

S&P SmallCap 600

Addition

McGrath RentCorp

MGRC

Industrials

Nov 4, 2026

S&P SmallCap 600

Deletion

Glaukos

GKOS

Health Care

Nov 4, 2026

S&P SmallCap 600

Addition

Loar Holdings

LOAR

Industrials

Nov 4, 2026

S&P SmallCap 600

Deletion

LiveRamp Holdings

RAMP

Information Technology

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/. 

FOR MORE INFORMATION:

S&P Dow Jones Indices
index_services@spglobal.com

Media Inquiries
spdji.comms@spglobal.com

View original content:https://www.prnewswire.com/news-releases/okta-set-to-join-sp-500-others-to-join-sp-midcap-400-and-sp-smallcap-600-302925405.html

SOURCE S&P Dow Jones Indices

Continue Reading

Technology

Tradier Brokerage Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After a Vendor Attack Exposes Social Security Numbers

Published

on

By

National class action law firm offers free, confidential case evaluations to Tradier Brokerage customers and others whose personal information may have been exposed.

NEWTOWN, Pa., Oct. 30, 2026 /PRNewswire/ — Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a data breach affecting Tradier Brokerage Inc., a Charlotte, North Carolina-based online broker-dealer. Anyone who received a breach notice or believes their information may have been exposed can request a free case evaluation.

What Happened

On August 28, 2026, a cyberattack targeted Etna Software Corporation, a third-party vendor that provides the order management system and pre-trade controls Tradier uses to operate its brokerage business. Tradier became aware of the incident on September 3, 2026. Tradier has said that its own internal network was not compromised and remained secure throughout the incident, and that the breach was limited to systems and data held by Etna.

Tradier began notifying affected customers by email and disclosed the incident to the California Attorney General. According to regulatory filings, the incident has affected 9,404 Texas residents and 1,580 Massachusetts residents so far. Tradier has said it is reviewing its third-party relationships and its data minimization program.

What Information Was Exposed

According to Tradier Brokerage, the personal information that may have been accessed includes:

Full namesAddressesPhone numbersSocial Security numbersGovernment-issued tax identification numbers

Because Social Security numbers and tax identification numbers are among the most sensitive categories of personal information, the exposure creates a heightened risk of identity theft and financial fraud for affected individuals.

Who May Be Affected

The investigation focuses on Tradier Brokerage customers whose personal information was held in the Etna systems used to operate Tradier’s brokerage business. Tradier has arranged with Cyberscout, a TransUnion company, to provide affected individuals up to two years of complimentary credit monitoring and identity theft protection; eligible individuals must enroll within 90 days of receiving their notification letter.

Your Legal Options

Edelson Lechtzin LLP is investigating a potential class action on behalf of individuals whose data may have been compromised. A successful case could recover compensation for losses such as lost time, out-of-pocket costs, and loss of privacy, and could press Tradier Brokerage to strengthen its data protection. The firm evaluates claims at no cost.

Recommended Steps to Protect Yourself

Watch for the notice from Tradier Brokerage and keep the enclosed code for the free credit monitoring being offered, enrolling within 90 days.

Place a free fraud alert or credit freeze with Equifax, Experian, and TransUnion, and obtain your free reports at AnnualCreditReport.com.Review your account statements for anything you do not recognize, and report suspected identity theft to the Federal Trade Commission at IdentityTheft.gov.

Contact Us for a Free Case Evaluation

Speak confidentially with a data privacy attorney: Marc Edelson, Esq., Edelson Lechtzin LLP, 411 S. State Street, Suite N-300, Newtown, PA 18940; Phone: 844-696-7492; Email: medelson@edelson-law.com; or click HERE to request a free consultation.

About Edelson Lechtzin LLP

Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. Beyond data breach litigation, the firm handles class and collective actions involving securities and investment fraud, antitrust violations, ERISA benefit plans, wage theft, and consumer fraud.

Media and Partnership Inquiries: Use the contact information above regarding interviews, co-counsel opportunities, and referral partnerships.

Legal Notice: This press release may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee a similar outcome.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tradier-brokerage-data-breach-investigation-edelson-lechtzin-llp-probes-class-action-claims-after-a-vendor-attack-exposes-social-security-numbers-302925353.html

SOURCE Edelson Lechtzin LLP

Continue Reading

Trending